LONDON, December 3 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global clinical research organization (CRO) providing clinical development and staffing services in Europe, the Americas and Asia, today announces the appointment of Dr. Sharon Moore as Executive Vice President, Global Quality Medical Affairs. Dr. Moore is based at Chiltern's Bristol, Tennessee, USA office.
Dr. Moore is a physician with 15 years of industry experience. Prior to joining Chiltern, Sharon served as a pharmacovigilance physician and practiced medicine, served as an investigator, was a member of an Institutional Review Board and authored several publications. She joined CTMS, a US CRO, in 1998. Sharon has served with Chiltern since the acquisition of CTMS in 2007 as Global Head of Quality Assurance and Executive Director, Medical Affairs. Sharon has Masters in Public Health (MPH) and Business Administration (MBA), holds an active medical license, and is a Certified Physician Investigator (CPI) through the Academy of Pharmaceutical Physicians and Investigators (APPI).
I am delighted to appoint Dr. Moore to lead our global quality and medical functions and to have her join our Group Executive Board, stated Glenn Kerkhof, CEO of Chiltern. This is a key scientific appointment and Dr. Moore brings a wealth of experience which will enhance our operational delivery and consultative approach for our clients.
Dr. Moore commented, I am excited about the opportunity to represent our global QA, Medical and Pharmacovigilance functions. We work in a dynamic environment with increasing complexity of clinical trials and growing importance of safety surveillance. Our teams are working to strengthen our services and to prepare for new medical developments.
Company profile
About Chiltern:
Established in 1982, Chiltern is a leading global clinical Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries and employs 1,400 people in 28 countries. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information: www.chiltern.com.
For More Information: Natalie Chong, Chiltern International Sue Ojanen, Chiltern International Ltd. Inc. 171 Bath Road 1241 Volunteer Parkway Slough, Berkshire SL1 4AA, UK Bristol, TN 37620, USA Tel: +44-(0)-1753-512-000 Tel: +1-423-968-9533 Email: natalie.chong@chiltern.com Email: sue.ojanen@chiltern.com
SOURCE: Chiltern
CONTACT: Natalie Chong of Chiltern International Ltd.,+44-(0)-1753-512-000, natalie.chong@chiltern.com, or Sue Ojanen of ChilternInternational Inc., +1-423-968-9533, sue.ojanen@chiltern.com
Comments